Moberg Pharma AB (STO:MOB.ST)

Sunday, September 29, 2024, 3:22 PM
TSSI, In the Company of XPEL and ZYXI, Finds Its Way To The Top 3 of Run to $1.00 (R21) Model Portfolio [GeoWire Weekly No. 155]
Sunday, September 15, 2024, 11:21 AM
With 45% Return From Buy on Pullback Portfolio #11 In The Books, BOP #12 and LifeVantage (LFVN) Fireside with CEO Take Center Stage [GeoWire Weekly No. 153]
See All GeoWire Weekly...
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

Web site: http://www.mobergpharma.se/

Last updated September 13, 2024


Market Data powered by QuoteMedia. Terms of Use